Loading
NASDAQHealthcareBiotechnology
Latest quote
$1.85
−$0.03 · -1.60%
Elicio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to creating a diverse array of innovative immunotherapies for the treatment of various cancers and other diseases. The company's primary experimental drug, ELI-002, is an AMP therapeutic vaccine specifically formulated to target KRAS-driven cancers. Its development portfolio also encompasses ELI-004, an AMP-modified CpG adjuvant that forms part of ELI-002; ELI-007, a lymph node-targeted AMP-peptide vaccine addressing mutant BRAF-driven cancers; and ELI-008, a multivalent lymph node-targeted AMP-peptide vaccine for cancers expressing mutant TP53. Furthermore, Elicio is advancing ELI-005, a vaccine candidate for preventing COVID-19, and ELI-011 for hematological malignancies. Another program, ELI-012, is an mKRAS TCR T cell AMP-lifier designed for combined use with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company's operations are headquartered in Boston, Massachusetts.
Previous close
$1.85
−$0.03 · -1.60%
After-hours
$1.85
$0.00 · 0.00%
Oct 7, 7:30 PM ET
Regular session · ET · Market data may be delayed.
Elicio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to creating a diverse array of innovative immunotherapies for the treatment of various cancers and other diseases. The company's primary experimental drug, ELI-002, is an AMP therapeutic vaccine specifically formulated to target KRAS-driven cancers. Its development portfolio also encompasses ELI-004, an AMP-modified CpG adjuvant that forms part of ELI-002; ELI-007, a lymph node-targeted AMP-peptide vaccine addressing mutant BRAF-driven cancers; and ELI-008, a multivalent lymph node-targeted AMP-peptide vaccine for cancers expressing mutant TP53. Furthermore, Elicio is advancing ELI-005, a vaccine candidate for preventing COVID-19, and ELI-011 for hematological malignancies. Another program, ELI-012, is an mKRAS TCR T cell AMP-lifier designed for combined use with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company's operations are headquartered in Boston, Massachusetts.
Day range
Current $1.85
52-week range
Current $1.85
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
26
Expensive
Sentiment
41
Mixed
Risk
76
High Risk
Momentum
19
Strong Down
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Elicio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to creating a diverse array of innovative immunotherapies for the treatment of various cancers and other diseases. The company's primary experimental drug, ELI-002, is an AMP therapeutic vaccine specifically formulated to target KRAS-driven cancers. Its development portfolio also encompasses ELI-004, an AMP-modified CpG adjuvant that forms part of ELI-002; ELI-007, a lymph node-targeted AMP-peptide vaccine addressing mutant BRAF-driven cancers; and ELI-008, a multivalent lymph node-targeted AMP-peptide vaccine for cancers expressing mutant TP53. Furthermore, Elicio is advancing ELI-005, a vaccine candidate for preventing COVID-19, and ELI-011 for hematological malignancies. Another program, ELI-012, is an mKRAS TCR T cell AMP-lifier designed for combined use with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company's operations are headquartered in Boston, Massachusetts.
Day range
Current $1.85
52-week range
Current $1.85
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | 28.31M USD |
| Cost of goods sold | 1.13M USD | 1.18M USD | 1.17M USD | 1.06M USD | 1.23M USD |
| Gross profit | −1.13M USD | −1.18M USD | −1.17M USD | −1.06M USD | 27.08M USD |
| Research and development | 24.9M USD | 33.66M USD | 22.68M USD | 17.05M USD | 48.61M USD |
| Selling, general, and administrative | 12.81M USD | 11.33M USD | 11.9M USD | 5.63M USD | 17.78M USD |
| Operating expenses | 36.59M USD | 43.81M USD | 34.58M USD | 22.68M USD | 66.39M USD |
| Interest income | 776K USD | 777K USD | 373K USD | 64.83K USD | 3.39K USD |
| Interest expense | 1.13M USD | 455K USD | 1.06M USD | 3.6M USD | 876.44K USD |
| Depreciation and amortization | 1.13M USD | 1.18M USD | 1.17M USD | 1.06M USD | 251.45K USD |
| Operating income | −37.71M USD | −44.99M USD | −35.75M USD | −23.73M USD | −39.31M USD |
| Net income | −39.57M USD | −51.9M USD | −35.2M USD | −28.21M USD | −26.4M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$11.83
539.46% upsideLimited analyst sample: 4 ratings. Interpret the distribution with caution.
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Jun 2, 2023 | 1:10 | — | — |
Effective Jun 2, 2023
1:10
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI1.12M0.00%2.3T USD0.03%$381.03-0.40%
iShares Russell 2000 ETFIWM607.32K0.00%78.56B USD0.19%$277.7-1.29%
Vanguard Extended Market ETFVXF387.71K0.00%95.4B USD0.05%$233.49-1.56%
iShares Russell 2000 Growth ETFIWO231.12K0.00%14.25B USD0.24%$355.37-1.43%
Vanguard Russell 2000 ETFVTWO204.31K0.00%18B USD0.06%$112.21-1.26%
iShares Micro-Cap ETFIWC94.26K0.01%1.33B USD0.60%$183.36-1.09%
Vanguard Russell 2000 Growth ETFVTWG38K0.00%1.7B USD0.06%$259.28-1.46%
iShares Russell 2500 ETFSMMD12.76K0.00%4.06B USD0.23%$85.85-1.46%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCVanguard Russell 2000 Growth ETFVTWGiShares Russell 2500 ETFSMMDAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
